Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Hormone Refractory Prostate Cancer Industry Expected To Reach By 2029, Starting From 2025 Levels?
The hormone-refractory prostate cancer market has demonstrated rapid growth in recent years. Its valuation is projected to increase from $7.35 billion in 2024 to $8.12 billion in 2025, expanding at a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to various factors such as the rising incidence of prostate cancer, an uptick in PSA (prostate-specific antigen) screening, enhanced physician awareness and specialization, increased utilization of palliative care, and a growing number of clinical trials.
The hormone-refractory prostate cancer market size is poised for significant expansion in the coming years. It is projected to achieve a value of $11.91 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period stems from factors such as the increasing application of genetic biomarkers, the rising embrace of precision medicine, the broadened availability of PARP inhibitors, improved global access to HRPC treatments, and the growing clinical adoption of combination regimens. Prominent trends for this period include the widespread use of combination therapies, advancements in radiopharmaceuticals, the utilization of next-generation sequencing (NGS), the integration of digital tools and remote monitoring, and the development of next-generation androgen receptor inhibitors and PARP inhibitors specifically for HRPC.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp
Which Drivers Are Supporting Growth Of The Hormone Refractory Prostate Cancer Market?
Increasing financial commitment to cancer investigation is anticipated to fuel the expansion of the hormone-refractory prostate cancer market moving ahead. This investment encompasses financial aid and resource allocation aimed at progressing novel methods for cancer identification, therapy, and prophylaxis. The uptick in cancer research funding is a direct response to the escalating worldwide prevalence of cancer, necessitating more potent and precise therapeutic interventions. Such financial backing in cancer research stimulates breakthroughs in managing hormone-refractory prostate cancer, facilitating sophisticated treatments like radioligand therapies and hormone-blocking agents. Additionally, it finances clinical studies and biomarker investigations, contributing to improved treatment accuracy and patient results. Illustratively, in August 2024, the Cancer Research Institute (CRI), a US-based nonprofit organization focused on advancing immunotherapy research, allocated approximately $22.8 million during the 2023–2024 fiscal year, supporting 64 new grants for investigators affiliated with 42 institutions spanning seven nations. Consequently, the expanding financial outlay in cancer research is a significant impetus behind the expansion of the hormone-refractory prostate cancer market.
What Are The Major Segment Categories Driving The Hormone Refractory Prostate Cancer Market Growth?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
What Key Innovation Trends Are Fueling Advancements In The Hormone Refractory Prostate Cancer Market?
Leading companies in the hormone-refractory prostate cancer market are concentrating on developing advanced treatments, such as intravenous radioligand therapy, to enhance survival rates for patients with resistant forms of the illness. Intravenous radioligand therapy functions as a targeted approach, utilizing radioactive molecules linked to ligands to identify and attach to cancer-specific markers, thereby destroying cancer cells internally while safeguarding surrounding healthy tissue. For example, in March 2025, Novartis AG, a pharmaceutical corporation from Switzerland, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which had secured approval from the Food and Drug Administration (FDA). This treatment is intended for earlier administration in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received an androgen receptor pathway inhibitor (ARPI) and are suitable for delaying chemotherapy. The expanded indication, derived from the Phase III PSMAfore trial, approximately triples the eligible patient demographic and indicated that Pluvicto decreased the risk of radiographic progression or death by 59%, and more than doubled median radiographic progression-free survival when compared to an ARPI change. Pluvicto stands as the first targeted radioligand therapy authorized for use before chemotherapy in this specific context, presenting a novel treatment alternative that postpones disease progression with a favorable safety profile.
Who Are The Major Companies Operating In The Hormone Refractory Prostate Cancer Market?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Hormone Refractory Prostate Cancer Market During The Forecast Period?
North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Hormone Refractory Prostate Cancer Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp
Browse Through More Reports Similar to the Global Hormone Refractory Prostate Cancer Market 2025, By The Business Research Company
Prostate Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Prostate Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model